) The DNA Sequencing and Analysis Core is now in its 4th year of highly successful operation. Initiated as a fledging operation after the inception of the CU Cancer Center, the Core has grown remarkably with now 112 user groups, of which most are Cancer Center members. In addition to performing DNA sequencing reactions, Core services include preparation of various DNA templates and assisting customers with all technical aspects of DNA sequencing and analysis. The Core also prepares high-density filter arrays using customer prepared libraries. In addition to service functions, Core personnel reported improvements in basic DNA sequencing chemistry that permit longer, more accurate read-lengths and improved mutation detection. To facilitate research efforts of the CU Hereditary Cancer Clinic, the Core now offers screening for the BRCA1/2 185delAG, 5382insC and 6174delT mutations. Especially as a consequence of the Genome Project, the demand for DNA sequencing will continue to expand significantly. During the next period of support, the Core intends to continue its state-of-the-art services to Cancer Center members. Research-based mutation/polymorphism screening is also likely to expand. Over the past 4 years samples sequenced have increased from 1501 to 9410 (526%) and charge back fees have increased from $43,095 to $187,136 (334%). Because of the large increase we have been able to reduce fees which has led to continued increases in core usage. The core has been used by members of 9 of the 10 Cancer Center programs. The core will move to the Fitzsimons campus with the Cancer Center during the next grant cycle.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046934-15S1
Application #
6664430
Study Section
Project Start
2002-05-06
Project End
2003-01-31
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
$250,404
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
New, Melissa L; White, Collin M; McGonigle, Polly et al. (2018) Prostacyclin and EMT Pathway Markers for Monitoring Response to Lung Cancer Chemoprevention. Cancer Prev Res (Phila) 11:643-654
Vartuli, Rebecca L; Zhou, Hengbo; Zhang, Lingdi et al. (2018) Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. J Clin Invest 128:2535-2550
Scott, Aaron J; Arcaroli, John J; Bagby, Stacey M et al. (2018) Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Mol Cancer Ther 17:2112-2122
da Silva, Raquel Frenedoso; Dhar, Deepanshi; Raina, Komal et al. (2018) Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators. Sci Rep 8:9540
Majtan, Tomas; Jones Jr, Wendell; Krijt, Jakub et al. (2018) Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria. Mol Ther 26:834-844
Dhar, Deepanshi; Deep, Gagan; Kumar, Sushil et al. (2018) Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells. Mol Carcinog 57:1166-1180
Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994
Branchford, B R; Stalker, T J; Law, L et al. (2018) The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 16:352-363
Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6
Ren, Shengxiang; Rivard, Christopher J; Yu, Hui et al. (2018) A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer 19:450-456

Showing the most recent 10 out of 1634 publications